FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

THURSDAY, Feb. 13, 2020 — A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S….
Source: Topamax